 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) has recently issued
clinical guidelines in relation to the management of insulin dependent diabetes, covering
patients living with type 1 and insulin dependent type 2 diabetes. This includes devices
to support blood glucose monitoring. These recommendations are now being implemented
by integrated care boards (ICBs).</p><p> </p><p>On 19 December 2023, NICE published
its final recommendation on the hybrid closed loop system for people with type 1 diabetes.
NICE has agreed with NHS England that all children and young people, women who are
pregnant or planning a pregnancy, and those people who already have an insulin pump
will be first to be offered a hybrid closed loop system as part of a 5-year roll-out
plan. NHS England has set out priorities for access, to help reduce healthcare inequalities
through their implementation plan.</p><p> </p><p>Responsibility for the delivery of
services and the implementation of NICE recommendations rests with the appropriate
National Health Service commissioner. As diabetes care is commissioned by local ICBs,
they are responsible for developing commissioning policies. ICBs must pay due regard
to NICE guidance, however local decision making applies in terms of deciding whether
to utilise their funding to implement the recommendation or not.</p>
|
|
